Novartis reported better-than-expected first-quarter earnings for 2025, with earnings per share (EPS) of $2.28 surpassing estimates of $2.11. The company's sales reached $13.23 billion, marking a 12% increase year-over-year. Key contributors to this growth included Entresto, which posted sales of $2.26 billion, up 22%, and Cosentyx, with $1.53 billion in sales representing an 18% increase. Other notable sales figures included Kisqali at $956 million, Promacta/Revolade at $546 million, and Pluvicto at $371 million. Novartis raised its full-year earnings guidance, citing strong growth in drugs such as Leqvio, Kisqali, and Kesimpta during the quarter. The company’s profit beat estimates, driven by medicines for breast cancer, multiple sclerosis, and psoriasis. Meanwhile, GSK also reported better-than-expected first-quarter results, with revenue of £7.52 billion exceeding estimates of £7.46 billion, and adjusted EPS of 44.9 pence versus an expected 40.6 pence. GSK’s growth was driven by strong sales of asthma, HIV, and oncology drugs, despite weaker vaccine sales. The company maintained its full-year sales growth forecast of 3% to 8% at constant exchange rates and adjusted EPS growth of 6% to 8%. AstraZeneca posted higher profits in the first quarter, supported by sales of its diabetes and cancer medicines. Additionally, British consumer healthcare group Haleon reported first-quarter organic revenue growth that exceeded expectations, driven by strong oral health product sales which offset weaknesses in respiratory and digestive health products. Smith+Nephew saw a 3.1% revenue increase in the first quarter and maintained its 2025 outlook despite challenges in China.